Ozempic Is About to Go Generic for Billions of People
Ozempic’s active ingredient, semaglutide, has lost patent protection in key markets like India and China as of March 20, 2026, enabling affordable generic versions for billions. This shift targets countries with massive populations facing obesity and diabetes, slashing prices from $100–200 monthly to as low as $15.
Patent Expiry Details
Novo Nordisk’s semaglutide patent expired on March 20, 2026, in India, China, Brazil, Turkey, South Africa, and Canada. Over 50 generic brands are entering India immediately, with similar floods expected elsewhere soon.
US patents remain protected until around 2031–2032, delaying generics there.
Price and Access Impact
Generics in India start at $14 monthly—88% cheaper than branded Ozempic—making treatment viable for 1.1+ billion overweight or diabetic adults in India and China. Analysts expect further drops amid competition from firms like Dr. Reddy’s, Cipla, and Sun Pharma.
Novo cut prices preemptively and sought blocks in some markets.
This democratizes GLP-1 drugs for weight loss and diabetes globally outside the US, potentially reshaping obesity care in emerging markets. Quality concerns and self-medication risks arise with rapid generic entry.
